State Street Corporation (STT) is reaffirmed as a Buy due to its robust earnings growth and attractive valuation despite a 107% total return since late 2022. The company posted 39% year-over-year adjusted EPS growth and 15% fee revenue growth, consistently beating analyst estimates for over 20 quarters. With a forward price-to-earnings ratio of 11.9x and analyst EPS growth forecasts of 18% in 2026, 11% in 2027, and 14% in 2028, STT offers a potential 26% upside plus a 2.3% dividend yield. The main risk is the sensitivity of STT’s fee income to equity market downturns, but long-term prospects remain strong due to AI-driven market tailwinds.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
